Stock Scorecard
Stock Summary for Acumen Pharmaceuticals Inc (ABOS) - $1.05 as of 5/30/2025 5:00:41 PM EST
Total Score
9 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ABOS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABOS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABOS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ABOS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ABOS (32 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ABOS
Financial Details for ABOS
Company Overview |
|
|---|---|
| Ticker | ABOS |
| Company Name | Acumen Pharmaceuticals Inc |
| Country | USA |
| Description | Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.05 |
| Price 4 Years Ago | 6.76 |
| Last Day Price Updated | 5/30/2025 5:00:41 PM EST |
| Last Day Volume | 248,173 |
| Average Daily Volume | 226,224 |
| 52-Week High | 3.60 |
| 52-Week Low | 0.85 |
| Last Price to 52 Week Low | 23.53% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 59.99 |
| Sector PE | 40.42 |
| 5-Year Average PE | -2.53 |
| Free Cash Flow Ratio | 2.10 |
| Industry Free Cash Flow Ratio | 19.17 |
| Sector Free Cash Flow Ratio | 31.66 |
| Current Ratio Most Recent Quarter | 8.02 |
| Total Cash Per Share | 0.50 |
| Book Value Per Share Most Recent Quarter | 2.57 |
| Price to Book Ratio | 0.40 |
| Industry Price to Book Ratio | 18.65 |
| Sector Price to Book Ratio | 29.96 |
| Price to Sales Ratio Twelve Trailing Months | 538.78 |
| Industry Price to Sales Ratio Twelve Trailing Months | 42.37 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.56 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 60,573,000 |
| Market Capitalization | 63,601,650 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -95.39% |
| Reported EPS 12 Trailing Months | -1.94 |
| Reported EPS Past Year | -0.48 |
| Reported EPS Prior Year | -1.71 |
| Net Income Twelve Trailing Months | -116,252,000 |
| Net Income Past Year | -102,329,000 |
| Net Income Prior Year | -52,371,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 30,159,000 |
| Total Cash Past Year | 35,627,000 |
| Total Cash Prior Year | 66,886,000 |
| Net Cash Position Most Recent Quarter | 1,411,000 |
| Net Cash Position Past Year | 7,178,000 |
| Long Term Debt Past Year | 28,449,000 |
| Long Term Debt Prior Year | 27,337,000 |
| Total Debt Most Recent Quarter | 28,748,000 |
| Equity to Debt Ratio Past Year | 0.86 |
| Equity to Debt Ratio Most Recent Quarter | 0.84 |
| Total Stockholder Equity Past Year | 181,816,000 |
| Total Stockholder Equity Prior Year | 266,973,000 |
| Total Stockholder Equity Most Recent Quarter | 155,521,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -102,561,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.69 |
| Free Cash Flow Past Year | -86,231,000 |
| Free Cash Flow Prior Year | -43,085,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.01 |
| MACD Signal | -0.02 |
| 20-Day Bollinger Lower Band | 0.79 |
| 20-Day Bollinger Middle Band | 1.22 |
| 20-Day Bollinger Upper Band | 1.66 |
| Beta | 0.09 |
| RSI | 47.35 |
| 50-Day SMA | 2.02 |
| 150-Day SMA | 3.96 |
| 200-Day SMA | 5.09 |
System |
|
| Modified | 5/29/2025 4:19:21 PM EST |